---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-027986"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:24:29.632135+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Roivant reports FY2024 GAAP income from continuing ops $4.2B on $5.3B Telavant gain; Q4 loss $182.5M

## Summary
- Net product revenue from VTAMA (psoriasis) $75.1M for FY2024; over 385K prescriptions since launch.
- Cash, cash equivalents and restricted cash $6.6B at March 31, 2024; after $648.4M share repurchase from Sumitomo, pro forma $5.9B.
- Non-GAAP loss from continuing operations $799.9M for FY2024 vs $924.3M prior year.
- Dermavant debt renegotiated reducing potential payments by over $300M; $225M reduction expected over next three fiscal years.
- Pipeline: Priovant to initiate pivotal brepocitinib trial in NIU in H2 2024; Immunovant expects 4-5 registrational studies by March 2025.

## SEC filing metadata
- accession: 0001140361-24-027986
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036124027986/0001140361-24-027986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036124027986/ef20030255_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-027986
- JSON: https://secwatch.observer/filing/0001140361-24-027986.json
- Plain text: https://secwatch.observer/filing/0001140361-24-027986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.